Breaking News
February 21, 2018 - Postnatal depression impacts mother-child relationships for longer time frame
February 21, 2018 - Study describes new protection mechanisms to fight neurodegeneration in Parkinson’s and Alzheimer’s
February 21, 2018 - Tiny ‘brains on chips’ reveal mechanisms underlying brain’s wrinkling process
February 21, 2018 - Bedfont Scientific makes FDA 510(k) submission for clearance of ToxCO monitor
February 21, 2018 - ‘Grey’s Anatomy’ Traumas Lack Realism
February 21, 2018 - Sleep quality improves with help of incontinence drug
February 21, 2018 - Scientists uncover genetic cause behind typhoid’s antibiotic resistance
February 21, 2018 - Study reveals a significant link between heavy alcohol use and dementia
February 21, 2018 - French scientists develop new wearable laser that eradicates skin conditions
February 21, 2018 - People with major depressive disorder have reduced arginine levels, study shows
February 21, 2018 - National Health Spending at $3.5 Trillion in 2017, CMS Says
February 21, 2018 - Substantial inequalities in cesarean births persist in many countries
February 21, 2018 - Early childhood immune signature predicts risk of developing asthma later on
February 21, 2018 - Stanford researchers explore how gut bacteria respond to common changes in habitat
February 21, 2018 - Household Products May Pollute the Air as Much as Your Car Does: Study
February 21, 2018 - Combo Bests Targeted Agent in mRCC
February 21, 2018 - Researchers discover brain pathway that dissociates opioid addiction from analgesia
February 21, 2018 - Scientists uncover how newly discovered gene helps grow blood vessels
February 21, 2018 - Brain’s quality control process holds clues to obesity’s roots
February 21, 2018 - Researchers to study whether menstrual cups can help prevent vaginal infections
February 21, 2018 - MS patients who feel stigmatized more likely to suffer from depression
February 21, 2018 - Vitamin D supplementation during pregnancy could protect against childhood obesity
February 21, 2018 - Lower-Quality Medical Tx Might Have Skewed Key PCI vs CABG Trials
February 21, 2018 - Love and fear are visible across the brain instead of being restricted to any brain region
February 21, 2018 - Researchers discover potential new antimalarial treatment targets
February 21, 2018 - Adults with congenital heart disease have increased risk for dementia, study finds
February 21, 2018 - Clinical trial studying type 1 diabetes reaches full enrollment
February 21, 2018 - Father’s stress affects the brain development of offspring, mice study shows
February 21, 2018 - ESRD Death Declines in Vasculitis Patients
February 21, 2018 - Taking ibuprofen for long periods found to alter human testicular physiology
February 21, 2018 - Google AI device could predict a person’s risk of a heart attack
February 20, 2018 - FDA Approves Domestic Source for Tc-99m Isotopes
February 20, 2018 - Sanofi rejects refund demand faces Philippine suit over dengue vaccine (Update)
February 20, 2018 - Researchers discover that activation of specific enzyme may help suppress tumor metastasis
February 20, 2018 - Blood or marrow transplantation survivors have higher risk of cognitive impairment
February 20, 2018 - Booze Beats Pot at Being Unhealthy: Oregon Poll
February 20, 2018 - Morning Break: ’20 Years Late’; Drugs in the Dirt; Catching Flu in the Dorm
February 20, 2018 - Another piece to the puzzle in naked mole rats’ long, cancer-free life
February 20, 2018 - Scientists identify four viruses that can produce insulin-like hormones
February 20, 2018 - New e-Health solution developed to prevent cardiovascular disease, dementia in senior citizens
February 20, 2018 - New genetic risk score could help guide screening decisions for prostate cancer
February 20, 2018 - Study finds higher risk of stroke among blacks with atrial fibrillation than whites
February 20, 2018 - Physical activity could be used as strategy for diabetes prevention
February 20, 2018 - Researchers develop sensing method for early detection of cancer and diabetes
February 20, 2018 - New wearable electronics could be game-changer for stroke rehabilitation
February 20, 2018 - Immune history influences person’s response to flu vaccine
February 20, 2018 - Research findings could help develop new drugs to prevent, treat dry eye disease
February 20, 2018 - Serenity Now! Learn to Have Patience with Patients
February 20, 2018 - Computer simulation addresses the problem of blood clotting
February 20, 2018 - Women with type 1 diabetes not protected against coronary artery disease
February 20, 2018 - Persistent bloating can be a sign of ovarian cancer, warns charity
February 20, 2018 - Trump administration proposes rule to loosen curbs on short-term health plans
February 20, 2018 - Key protein involved in epigenetic regulation of gene expression guides skin cell renewal
February 20, 2018 - Heart attack symptoms often missed in women
February 20, 2018 - Diagnosis of celiac disease takes 3.5 years for patients who do not report GI symptoms
February 20, 2018 - Study reveals functional dynamics of ion channels
February 20, 2018 - Study explores link between mortality risk and combustible tobacco use
February 20, 2018 - ‘She Trusted Me, and I’d Turned Her Away’
February 20, 2018 - AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies
February 20, 2018 - Fast food makes the immune system more aggressive in the long term
February 20, 2018 - Therapeutic target for glaucoma could have treatment ramifications for Alzheimer’s and Parkinson’s
February 20, 2018 - Overcoming Negative Reviews | Medpage Today
February 20, 2018 - MyD88—villain of allergies and asthma
February 20, 2018 - Food scientists develop rapid screening technique to detect pesticide residue in vegetables
February 20, 2018 - Lab-grown cerebellar cells may help explain how ASD develops at molecular level
February 20, 2018 - Scientists explore connection between bad sleep habits and stiff blood vessels
February 20, 2018 - New Treatment Apalutamide (Erleada) Approved for Prostate Cancer That Resists Hormone Therapy
February 20, 2018 - Do You Really Need My Signature on That?
February 20, 2018 - HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection
February 20, 2018 - Diabetes does not increase work-loss years due to early retirement
February 20, 2018 - Researchers aim to find out how PTSD affects decisions of police
February 20, 2018 - UH Cleveland Medical Center explores novel treatments for uterine fibroids
February 20, 2018 - Flu Vax Efficacy 25% Against Predominant H3N2 Strain So Far
February 20, 2018 - HIV screening most optimal at 25 years of age if no risk factors
February 20, 2018 - Loyola Medicine primary care physician offers advice to minimize risk of flu
February 20, 2018 - Safe sleep recommendations for parents that may help reduce child’s risk of SUID
February 20, 2018 - Why Do So Few Docs Have Buprenorphine Waivers?
February 20, 2018 - Low levels of alcohol good for the brain
February 20, 2018 - Experimental treatment improves invisible symptoms of a man with spinal cord injury
February 20, 2018 - Myriad’s EndoPredict offers better prediction of breast cancer recurrence, analysis shows
Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabozantinib Bests Everolimus in RCC with Bone Metastases

image_pdfDownload PDFimage_print

Action Points

  • Note that this post-hoc subgroup analysis of a clinical trial found that cabozantinib was superior to everolimus in terms of progression-free survival in patients with bone-metastatic renal cell carcinoma.
  • Small subgroup analyses like these are often overturned in dedicated studies, so caution is warranted in interpreting these results.

Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup analysis of a pivotal clinical trial.

Data from that trial, called METEOR (Metastatic Renal Cell Carcinoma Phase III Study Evaluating Cabozantinib vs Everolimus), showed that progression-free survival in patients with bone metastases was 7.4 months with cabozantinib versus 2.7 months with everolimus (HR 0.33; 95% CI 0.21-0.51), said Bernard Escudier, MD, of the Gustave Roussy Institute in Villejuif Cedex, France, and colleagues.

Median overall survival was also significantly longer with cabozantinib in patients with bone metastases (20 versus 12 months; HR 0.54; 95% CI 0.34-0.84), as was the objective response rate (17% versus 0%), the team reported online in the Journal of Clinical Oncology.

Improved progression-free survival, overall survival, and objective response rates were also found in patients on cabozantinib without bone metastases, the study authors noted.

“Bone metastases are associated with a poor prognosis in advanced renal cell carcinoma, and additional treatments for these patients are needed. Cabozantinib is a standard of care for previously treated patients with advanced renal cell carcinoma, with clinical benefits in progression-free survival, overall survival, and objective response rates that are observed irrespective of the presence of bone metastases. On the basis of these outcomes, cabozantinib represents a good treatment option for this difficult-to-treat patient population.”

However, one expert was less than impressed with the results of the analysis: Asked for his opinion, Brian Rini, MD, of the Cleveland Clinic, who was not involved with the study, told MedPage Today: “What this study really shows is that renal cell carcinoma patients do worse on everolimus, not that they do better on cabo. The response rate and median progression-free survival on cabo are identical in patients with and without bone metastases. Because everolimus patients with bone metastases do worse, the relative advantage is greater.

“As these are unplanned, post-hoc subset analyses, they need to be interpreted with extreme caution,” he said via email. “There may be a rationale to give cabo to renal cell carcinoma patients with bone metastases, but it requires additional prospective study to make definitive statements.”

In the study, 658 patients were randomly assigned 1:1 to receive either cabozantinib or everolimus from August 2013 to November 2014. Of these patients, 142 (22%) had bone metastases at baseline: 77 in the cabozantinib group and 65 in the everolimus group. Of the patients with bone metastases, 112 (79%) also had visceral metastases: 60 in the cabozantinib group and 52 in the everolimus group. Overall, baseline characteristics were similar in patients with and without bone metastases and between treatment groups.

The bone scan response was 20% (95% CI 12%-29%) in the cabozantinib group and 10% (95% CI 4%-20%) in the everolimus group. Bone biomarkers changed more in the cabozantinib group, including decreases in the bone formation marker PINP (procollagen type I N-terminal propeptide) and the bone resorption marker CTx (C-terminal telopeptide of type 1 collagen). The use of bone-targeted therapies was similar in both groups, which suggests that the changes were caused by the study treatment, Escudier and colleagues explained.

“Changes in bone biomarkers with cabozantinib may be a result of a general pharmacodynamic effect, because these changes were observed in both patients with bone metastases and those without bone metastases. Cabozantinib treatment has also been associated with a reduction in the levels of bone biomarkers in patients with prostate cancer and bone metastases, consistent with these results.”

Safety in patients with bone metastases was consistent with the safety profiles in the overall study population for both treatments, the team reported. In the cabozantinib group, common grade 3 or 4 adverse events included fatigue, diarrhea, and palmar-plantar erythrodysesthesia syndrome. In the everolimus group, adverse events were anemia, hyperglycemia, and lymphocytopenia.

“Bone metastases are associated with a poor prognosis and a reduced benefit from targeted therapies in patients with renal cell carcinoma,” the researchers concluded. “Although our study was not powered for statistical testing of the subgroup analyses, the values of the hazard ratios and medians for progression-free survival and overall survival for patients with bone metastases were notable and favored cabozantinib over everolimus.”

The study was funded by Exelixis.

Escudier reported financial relationships with Pfizer, Novartis, Bayer AG, Bristol-Myers Squibb, Ipsen, Exelixis, and Roche/Genentech.

Rini reported having no financial relationships.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles